CONTE LISA A 4

What Happened

• Lisa A. Conte, Chief Executive Officer & President of Jaguar Health (JAGX), was granted two awards on December 11, 2025: 28,592 restricted stock units (RSUs) and 28,592 option-type derivative awards. Both grants are reported at $0 in the Form 4 (grant value at issuance shown as $0). These are compensation awards (not open‑market purchases or sales).

Key Details

• Transaction date: December 11, 2025. Report filed: January 21, 2026 (appears to be late relative to the typical 2‑business‑day Form 4 deadline).
• Grants: 28,592 RSUs (reported as acquired) and 28,592 derivative awards (options) reported as acquired; price shown $0 for each line.
• Shares owned after transaction: not disclosed in the provided excerpt of the filing.
• Footnotes: awards granted under the issuer’s 2014 Stock Incentive Plan (F1); grants approved by the board on Dec 11, 2025 (F2).
• Filing timeliness: Form 4 filed ~41 days after the grant date — the filing appears late (investors should note potential reporting-delay implications).

Context

• RSU details: Each RSU represents a contingent right to one share; the RSUs vest on December 11, 2026 and vested shares will be delivered on the vesting date (F3).
• Option/derivative details: The derivative awards will vest ratably each month over 12 months from the grant date, subject to continued employment (F4). The Form shows these as grants (compensation), not exercises or immediate stock sales.
• For retail investors: grants are compensation tied to employment and vesting schedules; they are common and don’t by themselves indicate open‑market buying or selling by the insider.